imfinzi (durvalumab) plus bevacizumab met endpoints in emerald-1 phase iii results in liver cancer
Published 9 months ago • 167 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
2:09
safey findings of emerald-1: durvalumab, bevacizumab and tace in hcc
-
0:55
exploring durvalumab bevacizumab tace in hepatocellular carcinoma: emerald-1 insights
-
1:03
imfinzi® (durvalumab) plus chemotherapy approved in the us as the first immunotherapy regimen...
-
1:47
the potential of early treatment of smm with immunotherapy
-
31:30
pancreatic cancer and immunotherapy with dr. elizabeth m. jaffee
-
5:57
is joe tippens still cancer free?
-
51:47
artificial intelligence in precision oncology
-
1:43
phase ii pathway: adjuvant pembrolizumab in patients with hnsc cancer at high risk for recurrence
-
2:49
first-in-human trial of medi1191 plus durvalumab in patients with advanced solid tumors
-
3:18
cancer in all patients vanishes in new u.s drug trial; 'first time in history'
-
0:36
the potential of immunotherapies in the myeloma treatment landscape
-
0:43
multicolor immunofluorescence to predict melanoma immunotherapy responses
-
0:47
advice for physicians when managing bispecific antibody treatment for patients with myeloma
-
2:00
ribociclib in early breast cancer | nejm
-
1:09
david avigan on precision immuno
-
0:42
astrazeneca’s immunotherapy imjudo (tremelimumab) wins fda approval for liver cancer
-
1:35
rationale for using immunotherapies in the frontline treatment of multiple myeloma
-
2:28
improving immunotherapy for more effective blood cancer treatment